#Heart-Failure

3 stories

Research May 23, 2026 · View digest

Anglia Ruskin Meta-Analysis (May 20, Cardiovascular Diabetology - Endocrinology Reports): 90,000+ Patient Review Confirms Long-Term GLP-1 Cardiovascular Protection Across MACE, Heart Failure, Premature Death

Researchers at Anglia Ruskin University published a systematic review and meta-analysis in Cardiovascular Diabetology - Endocrinology Reports on May 20 covering long-term cardiovascular outcomes for glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. The review aggregated data from more than 90,000 participants across large international clinical trials. The headline finding: GLP-1 receptor agonists significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term in patients with established cardiovascular disease and high cardiovascular risk. The review extends the SELECT 20% MACE-reduction signal to the broader high-risk-CV population and joins the established cardiovascular-outcomes evidence base alongside the LEADER (liraglutide), SUSTAIN-6 (semaglutide), and STEP-HFpEF (semaglutide in heart failure) trial readouts. The Anglia Ruskin synthesis is the broadest evidence aggregation to date — directly relevant to the Medicare GLP-1 Bridge that begins July 1, 2026.

Research May 11, 2026 · View digest

Wilding ECO 2026 Pre-Print: Real-World GLP-1 Weight Loss Correlates With Reduced Osteoarthritis, CKD, OSA, and Heart Failure Complications

Prof. John Wilding (University of Liverpool) and colleagues will present at ECO 2026 a real-world observational study tracking obesity-linked complication rates by degree of GLP-1-driven weight loss. In the year following GLP-1 treatment initiation, 27.0% of patients had BMI reductions <5%, 22.4% had 5-<10%, 14.1% had 10-<15%, 15.8% had ≥15%, and 20.8% gained BMI. Over a mean 11-month follow-up, patients with ≥15% BMI reduction had 37% lower osteoarthritis odds, 30% lower CKD odds, 69% lower OSA odds, and 32% lower heart failure odds versus those with 0-5% reduction (all statistically significant except heart failure). Incidence per 1,000 person-years: 21.4 OA, 21.1 CKD, 20.3 OSA, 3.9 HF. The data quantifies the value of pushing for deeper weight loss rather than cruise-control dosing.

Clinical Trials April 13, 2026 · View digest

GLP-1 Drugs Reduce Heart Failure Hospitalization and Mortality by Over 40% in HFpEF Patients

A Mass General Brigham study of over 90,000 HFpEF patients published in JAMA found semaglutide reduced heart failure hospitalization or all-cause mortality by 42%, while tirzepatide achieved a 58% risk reduction compared with sitagliptin. Both drugs showed acceptable safety profiles with benefits appearing early in treatment.